ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2026
Silmitasertib, an FDA-designated orphan CK2 inhibitor, ameliorates neuropathology and motor dysfunction in a Huntington's disease mouse model.
Ross J Pelzel et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.